GLP-1 Weight Loss Drugs Linked to Decreased Physical Activity
Individuals using popular GLP-1 weight loss medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, may experience a reduction in physical activity, according to recent research. While these drugs are effective for weight loss, an analysis of Fitbit data revealed a drop in daily step counts and overall exercise levels after starting the medications. This trend raises concerns regarding the preservation of muscle mass and long-term health, as the drugs can reduce both fat and muscle.
New research suggests that individuals prescribed GLP-1 weight loss drugs, such as Ozempic, Wegovy, Mounjaro, and Zepbound, might experience a decrease in physical activity levels even as they lose weight.
Researchers analyzed Fitbit data to observe patterns in daily step counts and exercise levels. The findings indicated a consistent decline in physical activity among users after they began taking these medications.
This reduction in movement presents a potential concern for long-term health. GLP-1 drugs are known to reduce both fat and muscle mass. A concurrent decrease in physical activity could further impact muscle preservation, which is vital for strength and overall well-being.
According to Science Daily, these findings highlight an area for further consideration in the comprehensive health management of patients using GLP-1 medications.
Advertisement
AdSense slot • inline
